Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder (Q33964656)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

1 reference

based on heuristic

inferred from title

schizoaffective disorder

1 reference

based on heuristic

inferred from title

fatty acid composition

1 reference

based on heuristic

inferred from title

Joseph R Hibbeln

1

object named as

Joseph R Hibbeln

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

Kevin K Makino

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Catherine E Martin

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Faith Dickerson

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

John Boronow

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Wayne S Fenton

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

1 March 2003

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Biological Psychiatry

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

53

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

431-441

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Phospholipase A2 activity in serum of neuroleptic-naive psychiatric inpatients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Phospholipase A2 activity in Epstein-Barr virus-transformed lymphoblast cells from schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Cigarette smoking and serum lipid and lipoprotein concentrations: an analysis of published data

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Nutrient intake according to education, smoking, and alcohol in Italian women

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

31phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Asymmetry of temporal lobe phosphorous metabolism in schizophrenia: a 31phosphorous magnetic resonance spectroscopic imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Differential prevalence of cigarette smoking in patients with schizophrenic vs mood disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Red cell membrane fatty acids, cytosolic phospholipase-A2 and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Haloperidol improves membrane phospholipid abnormalities in temporal lobes of schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Phosphorus magnetic resonance spectroscopy in schizophrenia: correlation between membrane phospholipid metabolism in the temporal lobe and positive symptoms

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Phospholipase A2 and the hypofrontality hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

A red cell membrane abnormality in a subgroup of schizophrenic patients: evidence for two diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Effects of highly purified eicosapentaenoic acid and docosahexaenoic acid on hemodynamics in humans.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Essential fatty acids in plasma phospholipids in schizophrenics

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Comparison of measures of fatty acid intake by subcutaneous fat aspirate, food frequency questionnaire, and diet records in a free-living population of US men

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

No differences in phospholipase-A2 activity between acute psychiatric patients and controls

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Lateralized abnormality of high-energy phosphate and bilateral reduction of phosphomonoester measured by phosphorus-31 magnetic resonance spectroscopy of the frontal lobes in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Frontal lobe metabolism and cerebral morphology in schizophrenia: 31P MRS and MRI studies

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Phospholipid abnormalities in postmortem schizophrenic brains detected by 31P nuclear magnetic resonance spectroscopy: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Diet and lung cancer 20+ years later: More questions than answers?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Smoking and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Schizophrenic symptoms and dietary intake of n-3 fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Docosahexaenoic acid but not eicosapentaenoic acid lowers ambulatory blood pressure and heart rate in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Behavioral deficits associated with dietary induction of decreased brain docosahexaenoic acid concentration.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Phospholipase A(2)s and lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Elevated PLA2 activity in schizophrenics and other psychiatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Initial investigation of the left temporoparietal region in schizophrenia by 31P magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Increased platelet membrane lysophosphatidylcholine in schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Depleted red cell membrane essential fatty acids in drug-treated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Arachidonic Acid: A Common Link in the Biology of Schizophrenia?

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Association of the Ban I dimorphic site at the human cytosolic phospholipase A2 gene with schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

31P nuclear magnetic resonance spectroscopy: neurodevelopment and schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Chemistry of lipid peroxidation

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Cigarette smoke radicals and the role of free radicals in chemical carcinogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Sustained Remission of Positive and Negative Symptoms of Schizophrenia Following Treatment With Eicosapentaenoic Acid

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Comparison between fat intake assessed by a 3-day food record and phospholipid fatty acid composition of red blood cells: results from the Monitoring of Cardiovascular Disease-Lille Study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Formation and retention of cotinine during placental transfer of nicotine in human placental cotyledon

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Influence of nicotine and cotinine on retinal phospholipase A2 and its significance to macular function

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Frontal lobe membrane phospholipid metabolism and ventricle to brain ratio in schizophrenia: preliminary 31P-MRS and CT studies

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Relation of smoking and alcohol consumption to serum fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Genetic polymorphisms, lipoproteins and coronary artery disease risk

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Dietary change after smoking cessation: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

A controlled trial of prostaglandin E1 precursor in chronic neuroleptic resistant schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Schizophrenia, tardive dyskinesia and essential fatty acids

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Reduced phosphodiesters and high-energy phosphates in the frontal lobe of schizophrenic patients: a (31)P chemical shift spectroscopic-imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Increase of phosphodiesters during neuroleptic treatment of schizophrenics: a longitudinal 31P-magnetic resonance spectroscopic study

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Metabolism and effects on platelet function of the purified eicosapentaenoic and docosahexaenoic acids in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Reproducibility and validity of a semiquantitative food frequency questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Membrane phospholipid abnormalities in postmortem brains from schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Red blood cell membrane dynamics in schizophrenia. III. Correlation of fatty acid abnormalities with clinical measures

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2802%2901549-4

7 January 2021

Identifiers

10.1016/S0006-3223(02)01549-4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33964656&oldid=2225661362"